Clinical trials: Brain MRI
Central Nervous System Diseases
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
- Trial name
- NCT00395460
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), Magnevist
- Where
- 4 sites in China
- Volunteers
- 147 people
- Sponsor
- Bayer
Movement Disorders, Parkinson Disease
A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
The Infinity MRI PMCF was conducted as an international, multicenter, observational, prospective, single-arm, post-market clinical follow-up (PMCF) study.
- Conditions
- Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
- Trial name
- NCT03884231
- Testing
- Infinity DBS System with MR Conditional labelling
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 74 people
- Sponsor
- Abbott Medical Devices
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Brain Tumor
Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in…
- Trial name
- NCT02343991
- Testing
- Transcranial ExABlate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- InSightec
Traumatic Brain Injury
TBI MR Study 3 Houston Methodist
This hypothesis-generating feasibility study to determine potential associations between a broad range of clinical neurological symptoms and Magnetic Resonance Image (MRI), data, and clinical findings involved in mild traumatic…
- Trial name
- NCT02218216
- Testing
- MRI Diagnostic
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GE Healthcare
Primary Brain Tumor
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization…
- Trial name
- REMIND (NCT02034708)
- Testing
- Dotarem®, Gadovist®/Gadavist®
- Where
- 32 sites in United States, Colombia and 2 more
- Volunteers
- 279 people
- Sponsor
- Guerbet
Carotid Artery Diseases, Carotid Atherosclerosis
The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
The goal of this evaluation is to document the incidence of post procedure DW-MRI lesions (relative to baseline) in patients treated with the transcarotid artery revascularization (TCAR) procedure.
- Conditions
- Carotid Artery Diseases, Carotid Atherosclerosis, Carotid Stenosis, Carotid Artery Plaque
- Trial name
- DW-MRI-US (NCT03982420)
- Testing
- Transcarotid Revascularization (TCAR)
- Where
- 6 sites in United States, Spain
- Volunteers
- 55 people
- Sponsor
- Silk Road Medical
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Concussion, Traumatic Brain Injury
Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2
This is an open-label, non-randomized, prospective, multi-site, parallel group (segment), hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between…
- Trial name
- mTBI-phase2 (NCT02556177)
- Testing
- MRI
- Where
- 7 sites in United States
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- Quanti OBR (NCT05915728)
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine
- Where
- 85 sites in United States, Argentina and 14 more
- Volunteers
- 410 people
- Sponsor
- Bayer
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
CNS Lesion, Blood Brain Barrier Defect
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at…
- Trial name
- NCT02633501
- Testing
- P03277, Gadobenate dimeglumine, MRI
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 312 people
- Sponsor
- Guerbet
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01010932
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Guerbet
Depressive Disorder, Major
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated…
- Trial name
- NCT03854578
- Testing
- BI 1358894, Citalopram
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
The drug effects will be studied after a single dose of 50 milligram (mg) albiglutide and a single dose of 10 microgram exenatide, to gain insight into the central mechanisms of nausea associated with Glucagon-like peptide-1…
- Trial name
- NCT02802514
- Testing
- Albiglutide 50mg, Exenatide 10microgram
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01012674
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Guerbet
Central Nervous System Diseases
Safety and Efficacy of MultiHance in Pediatric Patients
The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.
- Trial name
- NCT00323310
- Testing
- gadobenate dimeglumine
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Bracco Diagnostics, Inc